Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Besse

Showing results (311-320 of 512) with videos related to

Pageof 52
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 20, 2022
Hypersensitivity Reactions to Selpercatinib Treatment With or Without Prior Immune Checkpoint Inhibitor Therapy in Patients With NSCLC in LIBRETTO-001Caroline E McCoach, Christian Rolfo, Alexander Drilon, et al.
Clinical Lung Cancer|June 6, 2022
Clinical Utility and Outcomes Impact of Crystal Digital PCR of Sensitizing and Resistance EGFR Mutations in Patients With Advanced Non-Small Cell Lung CancerMariona Riudavets, Virginie Lamberts, Damien Vasseur, et al.
Plos One|June 12, 2020
Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assayJordi Remon, Aurelie Swalduz, David Planchard, et al.
European Journal of Cancer (Oxford, England : 1990)|January 18, 2019
Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancerBenjamin P Levy, Giuseppe Giaccone, Benjamin Besse, et al.
Annales De Pathologie|December 14, 2020
[Thymoma and squamous thymic carcinoma diagnosis; experience from the RYTHMIC network]Lara Chalabreysse, Romain Dubois, Véronique Hofman, et al.
Journal for Immunotherapy of Cancer|November 29, 2024
Antecedent viral immunization and efficacy of immune checkpoint blockade: an extensive serum antibody profile to predict outcomes in non-small cell lung cancerFilippo G Dall'Olio, Wael Salem Zrafi, Quentin Blampey, et al.
European Journal of Cancer (Oxford, England : 1990)|November 1, 2019
EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic diseaseAntonin Levy, Lizza E L Hendriks, Thierry Berghmans, et al.
Med (New York, N.Y.)|May 19, 2022
Liquid biopsies for residual disease and recurrenceJonathan Chee Ming Wan, Tariq Imdadali Mughal, Pedram Razavi, et al.
European Journal of Cancer (Oxford, England : 1990)|June 17, 2019
Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitorsLizza E L Hendriks, Gerben Bootsma, Jean Mourlanette, et al.
Lung Cancer (Amsterdam, Netherlands)|December 2, 2017
Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patientsLaura Mezquita, Melinda Charrier, Laura Faivre, et al.
Pageof 52

Showing results (311-320 of 512) with videos related to

Sort By:
Pageof 52
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 20, 2022
Hypersensitivity Reactions to Selpercatinib Treatment With or Without Prior Immune Checkpoint Inhibitor Therapy in Patients With NSCLC in LIBRETTO-001Caroline E McCoach, Christian Rolfo, Alexander Drilon, et al.
Clinical Lung Cancer|June 6, 2022
Clinical Utility and Outcomes Impact of Crystal Digital PCR of Sensitizing and Resistance EGFR Mutations in Patients With Advanced Non-Small Cell Lung CancerMariona Riudavets, Virginie Lamberts, Damien Vasseur, et al.
Plos One|June 12, 2020
Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assayJordi Remon, Aurelie Swalduz, David Planchard, et al.
European Journal of Cancer (Oxford, England : 1990)|January 18, 2019
Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancerBenjamin P Levy, Giuseppe Giaccone, Benjamin Besse, et al.
Annales De Pathologie|December 14, 2020
[Thymoma and squamous thymic carcinoma diagnosis; experience from the RYTHMIC network]Lara Chalabreysse, Romain Dubois, Véronique Hofman, et al.
Journal for Immunotherapy of Cancer|November 29, 2024
Antecedent viral immunization and efficacy of immune checkpoint blockade: an extensive serum antibody profile to predict outcomes in non-small cell lung cancerFilippo G Dall'Olio, Wael Salem Zrafi, Quentin Blampey, et al.
European Journal of Cancer (Oxford, England : 1990)|November 1, 2019
EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic diseaseAntonin Levy, Lizza E L Hendriks, Thierry Berghmans, et al.
Med (New York, N.Y.)|May 19, 2022
Liquid biopsies for residual disease and recurrenceJonathan Chee Ming Wan, Tariq Imdadali Mughal, Pedram Razavi, et al.
European Journal of Cancer (Oxford, England : 1990)|June 17, 2019
Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitorsLizza E L Hendriks, Gerben Bootsma, Jean Mourlanette, et al.
Lung Cancer (Amsterdam, Netherlands)|December 2, 2017
Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patientsLaura Mezquita, Melinda Charrier, Laura Faivre, et al.
Pageof 52